^
Association details:
| Biomarker: | PD-L1 expression + REV3L overexpression |
|---|---|
| Cancer: | Urothelial Cancer |
| Drug: | Tevimbra (tislelizumab-jsgr) (PD1 inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
T-Cell, MHC i, and tumor intrinsic gene signatures predict clinical benefit and resistance to tislelizumab monotherapy in pretreated PD-L1+ urothelial carcinoma
Published date:
11/11/2020
Excerpt:
Gene expression profiling (GEP) was conducted on baseline tumor samples from 100 Chinese patients with UC enrolled in the phase 2 tislelizumab study...MTOR and REV3L were associated with shorter PFS (P=0.02; P=0.003) and OS (P=0.03; P =0.008), respectively...high expression of tumor intrinsic genes related to angiogenesis and the mTOR pathway may indicate resistance and suggest potential future drug combinations for these patients.
Trial ID:
